Florbetapir F18 Injection
Brand name: Amyvid
Public Citizen has been assessing the quality and efficacy of drugs and devices since its founding in 1971. We use the law, petitions, and letters to monitor the FDA and coax the agency into action. Our actions have contributed to many drugs being pulled off the market. Public Citizen has also been instrumental in getting “black box” and other warnings on drugs. Our advocacy work on this drug is available below.
If you are interesting in reading our evaluations of the safety and efficacy of medications as well as information on drug side effects and interactions, please visit WorstPills.org.
More information on florbetapir F18 injection (Amyvid)
- Letter to FDA Urging Rejection of Florbetapir F18 Injection (Amyvid) Based on Newly Published Expert Analysis, October 21, 2011
- Press Release: Public Citizen Exposes Serious Omissions in Published Study of Experimental Procedure for Diagnosing Alzheimer’s Disease, May 10, 2011
- Letter Encouraging Rejection of Florbetapir F18 Injection (Amyvid), February 21, 2011